

# LET'S RID THE WORLD OF RIBBONS




Immunotherapy has the promise to transform cancer treatment from patient care to patient cure. Let's put our heads together and change the world.

- PHENOPTICS™ RESEARCH PORTFOLIO
- Opal™ Multiplex Staining
- Vectra® 3 & Mantra™ Multiplex Biomarker Imaging Systems
- inForm® Image Analysis Software

## THE PROBLEM

**2X**  
2015 ..... 2030  
PROJECTED INCREASE IN CANCER DEATHS BY 2030

**>\$1 TRILLION**  
GLOBAL COST OF  
**CANCER**  
BY 2030




**1 IN 3**  
DIAGNOSED WITH CANCER IN THEIR LIFETIME

**24mil**

NEW CANCER CASES EXPECTED BY 2035

## THE PROMISE

SIDE EFFECTS FROM TREATMENT




**>1,200**  
IMMUNOTHERAPY CLINICAL TRIALS CURRENTLY UNDERWAY WORLDWIDE

**4** IMMUNOTHERAPEUTIC APPROACHES



## THE PARTNER





MULTIPLEX UP TO 6 BIOMARKERS IN A SINGLE TISSUE SECTION



**90**

PERCENT OF LEADING CANCER CENTERS USING PERKINELMER'S PHENOPTICS™ PORTFOLIO

VERIFIED PORTFOLIO OF  
**OPAL™**  
MULTIPLEX BIOMARKER ASSAYS



**2 DAYS vs 2 WEEKS**  
REDUCTION IN ANALYSIS TIMES WITH PHENOPTICS™ PORTFOLIO

For a complete listing of our global offices, visit [www.perkinelmer.com/ContactUs](http://www.perkinelmer.com/ContactUs)

Copyright ©2015, PerkinElmer, Inc. All rights reserved. PerkinElmer® is a registered trademark of PerkinElmer, Inc. All other trademarks are the property of their respective owners. For research use only. Not for use in diagnostic procedures.